Araten50 mg

Hypertension: It is recommended to use Araten 50 mg to treat hypertension. It could be used with other antihypertensive medications or taken alone (eg. thiazide diuretics). Renal Protection in Type-2 Diabetic Patients with Proteinuria: In hypertensive type-2 diabetics with proteinuria, which is defined as urine albumin to creatinine ratio >300 mg/g, Araten 50 mg is advised to postpone the advancement of renal disease.

Angiotensin-ll receptor blocker

The first angiotensin II receptor blocker that is orally active without a peptide is Araten 50 mg. It binds to the AT1 receptor, which is present in numerous tissues (such as the heart, kidneys, adrenal glands, and vascular smooth muscle), and inhibits several critical biological processes, such as vasoconstriction and the production of the hormone aldosterone that causes hypertension.

For the majority of patients, the beginning and maintenance dose is 50 mg once daily. Prior to raising the dose, 25 mg twice daily is advised if the antihypertensive impact of 50 mg once daily is insufficient. A starting dose of 25 mg once daily should be taken into consideration for individuals with intravascular volume depletion (such as those on high-dose diuretics). One or two doses of Araten 50 mg can be given each day. From 25 mg to 100 mg is the range for the total daily dose.

For the majority of patients, the beginning and maintenance dose is 50 mg once daily. Prior to raising the dose, 25 mg twice daily is advised if the antihypertensive impact of 50 mg once daily is insufficient. A starting dose of 25 mg once daily should be taken into consideration for individuals with intravascular volume depletion (such as those on high-dose diuretics). One or two doses of Araten 50 mg can be given each day. From 25 mg to 100 mg is the range for the total daily dose.

Levels of the Araten 50 mg active metabolite are decreased by rifampicin and fluconazole. The antihypertensive effects of hydrochlorothiazide and Araten 50 mg used together may be potentiated. Increases in serum potassium may result from the concurrent use of potassium-sparing diuretics (such as spironolactone, triamterene, and amiloride), potassium supplements, or salt substitutes containing potassium. The non-steroidal anti-inflammatory medicine indomethacin may lessen the antihypertensive effects of losartan. The risk of renal impairment is increased by the concurrent use of an ACE inhibitor, an angiotensin receptor antagonist, an anti-inflammatory medication, and a thiazide diuretic.

Pregnant women and individuals who are hypersensitive to any ingredient in this medication should not use Araten 50 mg. Those with diabetes shouldn't take Aliskiren and Araten 50 mg together.

Araten 50 mg side effects are minor and short-lived in nature. Dizziness, diarrhea, nasal congestion, coughing, and upper respiratory infections are the most frequent adverse effects. Fatigue, oedema, chest pain, nausea, headaches, and pharyngitis are other adverse effects.

Category D for pregnancies. If Araten 50 mg is given during the second or third trimester of pregnancy, the risk to the fetus increases. Given that numerous medicines are excreted in human milk and that it is unknown whether Araten 50 mg is one of them, a choice should be taken regarding whether to stop breastfeeding or stop taking the medication, taking into account the significance of the medication to the mother.

In addition to increasing fetal and neonatal morbidity and mortality, the use of Araten 50 mg throughout the second and third trimesters of pregnancy decreases fetal renal function. Symptomatic hypotension may happen in people who are intravascularly volume-depleted (such as those taking high-dose diuretics). Patients with cirrhosis have a considerably higher plasma concentration of Araten 50 mg. Patients with renal impairment have experienced changes in renal function, including renal failure.

Keep dry and away from heat and light. Keep out of children's reach.

Angiotensin-ll receptor blocker

The first angiotensin II receptor blocker that is orally active without a peptide is Araten 50 mg. It binds to the AT1 receptor, which is present in numerous tissues (such as the heart, kidneys, adrenal glands, and vascular smooth muscle), and inhibits several critical biological processes, such as vasoconstriction and the production of the hormone aldosterone that causes hypertension.

Category D for pregnancies. If Araten 50 mg is given during the second or third trimester of pregnancy, the risk to the fetus increases. Given that numerous medicines are excreted in human milk and that it is unknown whether Araten 50 mg is one of them, a choice should be taken regarding whether to stop breastfeeding or stop taking the medication, taking into account the significance of the medication to the mother.